This was the stock's second consecutive day of losses.

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Government dropped appeal of verdict that voided patents Critics warn pact’s precedent risks public health innovation Public health advocates expressed outrage at the US government’s settlement of its ...

The latest trading session saw Gilead Sciences (GILD) ending at $92.96, denoting a +1.22% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of ...

The website of newly created U.S. Department of Government Efficiency, headed by technocrat Elon Musk, started to display a dogecoin (DOGE) token logo on Tuesday, despite having no direct relation ...

Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) – Zacks Research boosted their Q2 2025 earnings per share estimates for Gilead Sciences in a report issued on Thursday, January 16th.

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

GS-1427 is under clinical development by Gilead Sciences and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition ...